ArticleCancer biology & medicine2016
Changing paradigm of cancer therapy: precision medicine by next-generation sequencing.
Article in Cancer biology & medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Comprehensive overview of AI methodologies in nano-drug delivery Optimization and Design.NPJ precision oncology · 2026Review
- Optimization of a hybridization-based target enrichment protocol for precision oncology.Molecular biology reports · 2026Article
- Innovative laboratory techniques shaping cancer diagnosis and treatment in developing countries.Discover oncology · 2025Review
- Prognostic value of theTherapeutic advances in medical oncology · 2024Article
- Evaluating a therapeutic window for precision medicine by integrating genomic profiles and p53 network dynamics.Communications biology · 2022Article
- Utility of Next-Generation Sequencing in the Reconstruction of Clonal Architecture in a Patient with anDiagnostics (Basel, Switzerland) · 2022Article
- Cancer Cure and Consequences on Survivorship Care: Position Paper from the Italian Alliance Against Cancer (ACC) Survivorship Care Working Group.Cancer management and research · 2022Article
- Chromosomal barcoding of E. coli populations reveals lineage diversity dynamics at high resolution.Nature ecology & evolution · 2020Article
- Single Cell Transcriptome in Colorectal Cancer-Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells.Frontiers in pharmacology · 2020Review
- Article
- Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology.Cancer biology & medicine · 2019Article
- Tumor Tissue Explant Culture of Patient-Derived Xenograft as Potential Prioritization Tool for Targeted Therapy.Frontiers in oncology · 2019Article
- Article
- Biomarkers: Delivering on the expectation of molecularly driven, quantitative health.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- Somatic Mutations Activating the mTOR Pathway in Dorsal Telencephalic Progenitors Cause a Continuum of Cortical Dysplasias.Cell reports · 2017Article
- Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.Nature communications · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine aims to identify the right drug, for the right patient, at the right dose, at the right time, which is particularly important in cancer therapy. Problems such as the variability of treatment response and resistance to medication have been long-standing challenges in oncology, especially for development of new medications. Solid tumors, unlike hematologic malignancies or brain tumors, are remarkably diverse in their cellular origins and developmental timing. The ability of next-generation sequencing (NGS) to analyze the comprehensive landscape of genetic alterations brings promises to diseases that have a highly complex and heterogeneous genetic composition such as cancer. Here we provide an overview of how NGS is able to facilitate precision medicine and change the paradigm of cancer therapy, especially for solid tumors, through technical advancements, molecular diagnosis, response monitoring and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.